AABB will host a Hot Topic Discussion on Aug. 18 to discuss the potential impact of long-acting, injectable cabotegravir as pre-exposure prophylaxis (PrEP) for the prevention of HIV. The Food and Drug Administration approved the injectable medication (Apretude, Viiv Healthcare) in December 2021.
Studies have demonstrated that cabotegravir can linger in the body for up to 12 months or longer following injection, presenting new considerations for donor testing and screening. In this program, expert speakers will provide brief presentations on these considerations, followed by a question and discussion period.
The program will take place from 2-3:15 p.m. ET on Thursday, Aug. 18. Registration is complimentary to AABB individual members through the generous support of Ashland, an AABB Premium Corporate Partner. Non-members may purchase registration.